TY - JOUR
T1 - Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes
AU - Baba, Yuichi
AU - Higa, Jason K.
AU - Shimada, Briana K.
AU - Horiuchi, Kate M.
AU - Suhara, Tomohiro
AU - Kobayashi, Motoi
AU - Woo, Jonathan D.
AU - Aoyagi, Hiroko
AU - Marh, Karra S.
AU - Kitaoka, Hiroaki
AU - Matsui, Takashi
N1 - Funding Information:
This work was supported, in part, by a research grant from Kochi Organization for Medical Reformation and Renewal, Japan (to Y. Baba), a research grant from the Mitsukoshi Health and Welfare Foundation, Japan (to T. Suhara), National Institutes of Health (NIH) Training Grant T32-HL-115505 (to B. K. Shimada) and Grants P30-GM-103341 and P20-GM-113134 (to T. Matsui) and G12-MD-007601 to the Histopathology Core, University of Hawaii at Manoa.
Publisher Copyright:
© 2018 the American Physiological Society.
PY - 2018/4
Y1 - 2018/4
N2 - Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2’,7’-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis.
AB - Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2’,7’-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis.
KW - Cardiomyocyte
KW - Ferroptosis
KW - Iron
KW - Mechanistic target of rapamycin
UR - http://www.scopus.com/inward/record.url?scp=85045448588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045448588&partnerID=8YFLogxK
U2 - 10.1152/ajpheart.00452.2017
DO - 10.1152/ajpheart.00452.2017
M3 - Article
C2 - 29127238
AN - SCOPUS:85045448588
SN - 0363-6135
VL - 314
SP - H659-H668
JO - American Journal of Physiology
JF - American Journal of Physiology
IS - 3
ER -